The proteinase-activated receptors (PARs) are widely recognized for their modulatory properties of infl ammation and neurodegeneration. We investigated the role of PAR 2 in the pathogenesis of multiple sclerosis (MS) in humans and experimental autoimmune encephalomyelitis (EAE) in mice. PAR 2 expression was increased on astrocytes and infi ltrating macrophages in human MS and murine EAE central nervous system (CNS) white matter (P < 0.05). Macrophages and astrocytes from PAR 2 wild-type (WT) and knockout (KO) mice exhibited differential immune gene expression with PAR 2 KO macrophages showing significantly higher interleukin 10 production after lipopolysaccharide stimulation (P < 0.001). PAR 2 activation in macrophages resulted in the release of soluble oligodendrocyte cytotoxins (P < 0.01). Myelin oligodendrocyte glycoprotein-induced EAE caused more severe infl ammatory gene expression in the CNS of PAR 2 WT animals (P < 0.05), together with enhanced T cell proliferation and interferon production (P < 0.05), compared with KO littermates. Indeed, PAR 2 WT animals showed markedly greater microglial activation and T lymphocyte infi ltration accompanied by worsened demyelination and axonal injury in the CNS compared with their PAR 2 KO littermates. Enhanced neuropathological changes were associated with a more severe progressive relapsing disease phenotype (P < 0.001) in WT animals. These fi ndings reveal previously unreported pathogenic interactions between CNS PAR 2 expression and neuroinfl ammation with ensuing demyelination and axonal injury.
Proteinase-activated receptors (PARs) are a family of G protein-coupled receptors that are widely expressed on neurons and glial cells in the nervous system (1) . PARs are activated through proteolytic cleavage of their extracellular NH 2 terminus. The proteolytic cleavage unmasks a "tethered ligand" that binds intramolecularly to the receptor and initiates a signal transduction event (2) . Among the four PARs identifi ed to date, PAR 1 , PAR 3 , and PAR 4 can be activated by thrombin, whereas trypsin and mast cell tryptase can activate PAR 2 (2, 3) . Signaling through diff erent heterotrimeric G proteins, PARs can aff ect various cellular functions in the nervous system, including neural cell proliferation, gene transcription, diff erentiation, and survival (4, 5) . The role of PAR 2 , which is widely distributed throughout the nervous system, has been principally investigated in the peripheral nervous system, where it is known to play major roles in injury, infl ammation, neuronal signaling, and nociception (6, 7) . PAR 2 is also known to be expressed on neurons and astrocytes in rodent and human central nervous systems (CNS), and several studies have implicated it in the pathogenesis of ischemia and neurodegeneration (8-10).
Multiple sclerosis (MS) is a common immune-mediated neurological disorder, which is histopathologically characterized by infi ltration of the CNS with infl ammatory leukocytes followed by demyelination and axonal loss (11) (12) (13) . It is generally accepted that an autoimmune response directed against components of myelin is the chief pathogenic event during MS (14) . The exact mechanisms leading to the generation of autoimmune responses in MS are not fully known, although components of both the adaptive and innate immune systems are involved (15, 16) . Experimental autoimmune encephalomyelitis (EAE) is a widely studied animal model for MS, which recapitulates many of the clinical and neuropathologic aspects of MS (17) . EAE can be induced by immunization of genetically susceptible animals with diff erent antigenic (A) PAR 2 mRNA levels were increased in CNS white matter of MS patients (n = 6) compared with non-MS patients (n = 6), but (B) trypsin ogen mRNA levels were not signifi cantly different between the two groups. RFC, relative fold change. Student's t test; *, P < 0.05. (C) PAR 2 immunoreactivity was present on perivascular and parenchymal (C, inset) cells in MS white matter, but not in non-MS (D) CNS tissues. Immu nolabeling with the anti-CD45 (E) or the anti-GFAP antibodies (F) revealed colocalization of PAR 2 on leukocytes and astrocytes in CNS white matter of MS patients in the areas of active demyelination. Original magnifi cation, 400. (G) Flow cytometric analysis of PBMCs from healthy donors disclosed the expression of PAR 2 on resting and PHA-stimulated monocytes, whereas (H) expression levels were minimal on resting or PHA-treated lymphocytes. BV, blood vessel.
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components of CNS myelin, including myelin basic protein (MBP), proteolipid protein, or myelin oligodendrocyte glycoprotein (MOG). Immunization leads to the generation of myelin-reactive T cells in the periphery, which then migrate into the CNS and initiate autoimmune infl ammation. Although considered largely a T cell-mediated disease, there is increasing evidence for the involvement of other immune cells, including activated macrophages and microglia in both the initiation as well as the eff ector phases of the immune response associated with the EAE and MS pathogenesis (16, 18) . Herein, the expression levels and the cell types expressing PAR 2 were investigated in the CNS of MS and control patients. Using EAE as an animal model of MS, we explored the role of PAR 2 activation on astrocytes and monocytoid cells. Experiments were performed to evaluate the impact of PAR 2 -defi cient signaling on the generation and responsiveness of myelin-reactive T cells and the severity of MOGinduced EAE.
RESULTS PAR 2 expression is increased in the white matter during MS and EAE PAR 2 has been shown to be widely expressed on neurons and astrocytes in the CNS (19, 20) . To investigate the role of PAR 2 in the neuroinfl ammatory process associated with MS, we examined PAR 2 transcript levels in CNS white matter from MS and non-MS patients. RT-PCR analysis showed signifi cantly higher PAR 2 transcript levels in the white matter of MS compared with non-MS patients (Fig. 1 A) . Transcript levels of trypsinogen, a potential PAR 2 -activating proteinase, were not diff erent between MS and non-MS CNS tissues (Fig. 1 B) . Immunohistochemical staining showed that PAR 2 immunoreactivity was markedly enhanced in MS (Fig. 1 C) compared with non-MS white matter (Fig. 1 D) . In MS CNS tissues, PAR 2 immunoreactivity was chiefl y detected on infi ltrating perivascular cells together with parenchymal glial cells in the areas of active demyelination (Fig. 1 E) . Indeed, PAR 2 immunoreactivity was colocalized with CD45 leukocyte/macrophage marker in perivascular cells (Fig. 1 E) and with glial fi brillary acidic protein (GFAP) astrocytic marker in parenchymal cells (Fig. 1 F) . PAR 2 immunoreactivity was present on neurons in the gray matter with no obvious diff erences between groups (not depicted). Previous studies of blood-derived mononuclear cells have reported that monocytes but not lymphocytes express PAR 2 , and moreover, the expression levels increase upon diff erentiation to macrophages (21, 22) . We also examined PAR 2 expression in PBMCs from healthy human volunteers. Flow cytometric analysis showed PAR 2 expression on the monocyte population ( Fig. 1 G) , whereas expression on lymphocytes was minimal (Fig. 1 H) . Treatment of PBMC cultures with phytohemagglutinin for 24 h resulted in a marked up-regulation of PAR 2 immunoreactivity on monocytes ( Fig.  1 G) , but the PAR 2 immunoreactivity on the lymphocyte population was unaff ected (Fig. 1 H) . Thus, these observations indicated that monocytes rather than lymphocytes were the chief cell type expressing PAR 2 in both blood and brain, in support of previous studies (21, 22) .
Given that the EAE animal model recapitulates many of the neuropathological and clinical features of MS, together with similar underlying pathogenic mechanisms, we next examined PAR 2 expression in the CNS of mice with EAE. Interestingly, RT-PCR analysis showed signifi cantly higher levels for PAR 2 mRNA in the CNS of animals with EAE compared with healthy control mice (Fig. 2 A) . Similar to the MS CNS samples, PAR 2 immunoreactivity was detectable in the white matter of EAE animals, where it was localized chiefl y on GFAP-immunopositive astrocytes (Fig. 2 C, top) and ionized calcium binding adaptor protein (Iba-1)-immunopositive macrophage/microglia (Fig. 2 C, bottom) . Hence, these fi ndings indicated that PAR 2 expression was up-regulated on both glial cells and infi ltrating leukocytes during MS/ EAE-associated neuroinfl ammation.
PAR 2 defi ciency regulates immune gene expression in macrophages and astrocytes
Previous studies have demonstrated important roles for PAR 2 in modulating infl ammatory processes in the central and peripheral nervous systems (23, 24) . As macrophage/microglial activation followed by subsequent demyelination and astrocytosis are predominant neuropathologic features of MS and EAE (25) , we investigated the eff ects of PAR 2 expression on the production of infl ammatory mediators by these cells. After LPS treatment for 8 h, mRNA levels of proinfl ammatory or antiinfl ammatory mediators TNF-α (Fig. 3 A) , IL-1β (Fig.  3 B) , inducible nitric oxide synthase (iNOS) (Fig. 3 C) , and IL-10 ( Fig. 3 D) were analyzed in primary astrocytes and macrophages from PAR 2 WT and KO mice. Similar levels of TNF-α (Fig. 3 A) , IL-1β (Fig. 3 B) , and iNOS ( Fig. 3 C) mRNA were observed in PAR 2 WT and KO macrophages. However, PAR 2 -defi cient macrophages showed signifi cantly higher levels of IL-10 mRNA after LPS treatment (Fig. 3 D) . Gene expression analysis also showed signifi cantly higher levels of iNOS mRNA (Fig. 3 G) in PAR 2 WT astrocytes after LPS treatment, whereas TNF-α (Fig. 3 E) , IL-1β (Fig. 3 F) , and IL-10 ( Fig. 3 H) levels did not diff er between WT and KO astrocytes. Thus, these observations revealed a diff erence in the expression of immune genes between PAR 2 WT and KO astrocytes and macrophages, which depended on the individual cell type.
PAR 2 activation mediates oligodendrocyte toxicity
Acute demyelinating lesions in MS are believed to be generated by infi ltrating leukocytes and activated microglia that destroy myelin in the presence of autoreactive T cells (26, 27) . However, oligodendrocyte injury and apoptosis, even in the absence of a substantial infl ammatory reaction, have also been reported to be a principal pathological feature in newly forming lesions (28, 29) . We investigated the indirect eff ects of PAR 2 activation on macrophages and astrocytes in terms of oligodendrocyte viability. Supernatants from cultured murine macrophages or astrocytes, treated with the PAR 2 -activating peptide (PAR 2 AP) SLIGRL-NH 2 or the mutant inactive peptide (mAP) LSIGRL-NH 2 , were applied to oligodendrocyte cultures for 24 h, and the surface area of GalC-immunopositive oligodendrocytes as well as the number of cells with processes were quantifi ed. Interestingly, supernatants of PAR 2 AP-treated, but not mAP-or mock-treated macrophages, caused a marked reduction in the surface area of exposed oligodendrocytes, leaving a higher number of cells with fewer or no processes (Fig. 4 A) . Quantifi cation of the oligodendrocyte area and the number of cells with processes showed signifi cant reductions in cultures treated with the supernatants from and KO astrocytes, whereas (G) iNOS mRNA levels are signifi cantly higher in WT astrocytes after LPS stimulation. All experiments were performed in triplicate. RFC, relative fold change. Student's t test; ***, P < 0.001.
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PAR 2 AP-stimulated macrophages compared with mockor mAP-treated macrophages (Fig. 4 B) . Conversely, supernatants of PAR 2 AP-treated astrocytes did not aff ect oligodendrocyte morphology and surface area (Fig. 4 C) . Gene expression studies revealed a signifi cant induction of TNF-α (Fig. 4 D) , iNOS (Fig. 4 E) , IL-6 (Fig. 4 F) , and IL-12p40 (Fig. 4 G) transcript levels in PAR 2 AP-treated macrophages compared with mAP-or mock-treated cells. In addition, IL-1β, IFN-inducible protein 10, monocyte chemoattractant protein 1, and macrophage infl ammatory protein 1α transcripts were increased signifi cantly in PAR 2 AP-treated macrophages, but not in mAP-or mock-treated cells (not depicted). The same eff ects were not observed for PAR 2 AP-treated astrocytes (not depicted). Thus, these fi ndings revealed that direct activation of PAR 2 on macrophages caused oligodendrocyte injury associated with infl ammatory gene expression, which might contribute to demyelination in MS.
PAR 2 defi ciency reduces neuroinfl ammation and T cell proliferation during EAE
Given the higher expression of PAR 2 in human MS CNS white matter and its contribution to infl ammatory gene expression and oligodendrocyte injury, we next investigated the potential role of PAR 2 in EAE, as an animal model of MS, using PAR 2 WT and KO mice. We examined MOGinduced EAE in 10-12-wk-old PAR 2 KO mice compared with their WT littermate controls and corresponding healthy ( intact) controls. Neuropathological examination of the CNS of WT animals with EAE showed markedly enhanced immunoreactivity for macrophage/microglial marker, Iba-1, compared with PAR 2 KO EAE animals and the nonimmunized intact group (Fig. 5 A, fi rst column) . Iba-1-immunopositive cells showed hypertrophy and were more frequently detected in WT and PAR 2 KO EAE groups compared with the quiescent morphology observed in the nonimmunized intact group. Quantitative analysis showed a signifi cantly higher number of Iba-1-immunopositive cells in the PAR 2 WT EAE group compared with PAR 2 KO EAE animals (Fig. 5 B) . MBP immunoreactivity showed disrupted integrity of the myelin in both PAR 2 WT and KO EAE groups with much more severe demyelination in WT animals ( Fig. 5 A, second  column) , as indicated by quantitative analysis of MBPimmuno positive areas of the white matter (Fig. 5 C) . Indeed, myelin loss was closely associated with macrophage infi ltration/microglial activation, as indicated by merged MBP-Iba-1 immunoreactivity (Fig. 5 A, third column) . CD3 + T cells were also detectable in spinal cords after EAE induction (Fig.  5 A, fourth column) , with the WT EAE group showing a signifi cantly higher number of positive cells compared with KO EAE animals (Fig. 5 D) . Silver staining followed by counting of the axonal number also showed a signifi cant reduction in the number of axons in the PAR 2 WT EAE group compared with the KO EAE and control groups (Fig. 5 E) . Of note, PAR 2 WT and KO nonimmunized (intact) animals did not diff er in terms of neuropathological features and therefore were pooled for these quantitative analyses. Overall, these fi ndings indicated that defi cient PAR 2 signaling reduced neuroinfl ammation with greater preservation of myelin and proximate axons in the CNS during MOG-induced EAE.
The generation of myelin-reactive T cells in the peripheral immune system with their subsequent infi ltration of the CNS has been considered a key event in EAE and MS pathogenesis (11) . To examine the proliferative and cytokine response of T cells in MOG-immunized PAR 2 WT and KO animals, we measured [ 3 H]thymidine incorporation and intracellular IFN-γ immunoreactivity by FACS in lymphocytes cocultured with MOG-loaded irradiated splenocytes. Proliferation of T cells measured by [ 3 H]thymidine incorporation was signifi cantly higher in WT animals compared with their PAR 2 KO littermates (Fig. 6 A) . Intracellular cytokine assays showed a signifi cant increase in IFN-γ reactivity of CD3: CD4 but not CD3:CD8 immunopositive lymphocytes of WT animals compared with PAR-2 KO littermates (Fig. 6 , B and C). These observations disclosed that despite the absence of PAR 2 on lymphocytes, there was a signifi cant difference in T cell reactivity at the level of proliferative and cytokine responses after MOG immunization of WT and KO animals.
Enhanced host immune responses are apparent within the CNS during MS and EAE (13) . Gene expression studies of WT and KO animals showed signifi cantly higher levels of TNF-α (Fig. 7 A) , iNOS (Fig. 7 B) , IL-6 (Fig. 7 C) , and IFN-γ (Fig. 7 D) mRNA in the CNS of WT animals with 
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EAE compared with their PAR-2 KO littermates. TNF-α, iNOS, IL-6, and IFN-γ mRNA was detectable in PAR 2 WT and KO animals without EAE (intact) with no diff erence between the two groups (Fig. 7, A-D) . Together with diff erences in the neuropathological fi ndings and T cell reactivity, these observations emphasized the role of PAR 2 -defi cient signaling in mitigating MOG-induced autoimmune processes.
PAR 2 defi ciency is neuroprotective during EAE Consistent with the diff erences in infl ammatory gene expression, T cell response, and neuropathologic fi ndings in EAE induced in PAR 2 WT and KO animals, we observed a signifi cant diff erence in the neurobehavioral phenotype severity between PAR 2 WT and KO animals after the induction of EAE. Displaying a progressive relapsing disease course (Fig. 8 A) , PAR 2 WT animals showed a signifi cantly earlier disease onset together with signifi cantly more severe neurological disability during the course of the disease. In addition, maximal disease score (Fig. 8 B) and cumulative neurological disability (Fig. 8 C) were signifi cantly higher for WT EAE animals compared with the KO EAE group. Hence, our fi ndings indicated that PAR 2 expression contributed to the severity of neuroinfl ammation and neurological disability during MOGinduced EAE.
DISCUSSION
This study highlights previously unrecognized interactions between PAR 2 expression and induction of neuroinfl ammation during MS/EAE, thereby disclosing new therapeutic opportunities for CNS autoimmune demyelinating disorders. We have demonstrated that PAR 2 expression is enhanced in the CNS white matter during MS and EAE in which it is chiefl y expressed on perivascular macrophages and astrocytes (Fig. 9) . PAR 2 WT and defi cient macrophages and astrocytes exhibited diff erential infl ammatory gene expression, with PAR 2 activation on macrophages leading to the induction of proinfl ammatory cytokines and chemokines adversely aff ecting oligodendrocyte viability (Fig. 9) . Indeed, absent PAR 2 signaling suppressed EAE disease severity, which was associated with decreased T cell reactivity and neuroinfl ammation.
It is widely recognized that autoreactive T cells infi ltrating the white matter during MS initiate demyelination through the release of toxins together with recruiting and activating monocytoid cells (16) . However, an alternative view holds that oligodendrocyte death, perhaps due to apoptosis, together with microglial activation in the absence of marked lymphocyte infi ltration might herald newly forming de myelinating lesions (29) . Indeed, several studies indicate that innate immune mechanisms are potent determinants of MS and EAE disease onset and severity (30) (31) (32) (33) . Extensive oligodendrocyte death likely overwhelms normal mechanisms of dead cell clearance, prompting a T cell-mediated infl ammatory response that arises from the release of myelin antigens (29) . In this study, we observed less T cell reactivity and infi ltration after EAE induction in PAR 2 -defi cient mice, which may partly explain the milder disease severity in this group of animals compared with their WT littermates. Nonetheless, we also found that PAR 2 activation on macrophages led to the production of soluble cytotoxic factors, which diminished oligodendrocyte viability. These two observations could be considered reciprocal mechanisms by which PAR 2 expression aff ects the underlying pathogenic processes in EAE, likely refl ecting the interaction of the adaptive and innate immune systems. However, it is also plausible that PAR 2 expression and activation on monocytoid cells (unlike astrocytes) contributes directly to oligodendrocyte injury (34) , which could prime a subsequent myelin-specifi c T cell response, as mentioned above.
A recent study has reported a neuroprotective role for neuronal PAR 2 in experimental stroke (35) . Moreover, our group showed a neuroprotective role for neuronal PAR 2 expression and activation in the context of HIV-induced dementia, a neurodegenerative disorder caused by the HIV infection of brain (24) . Herein, up-regulation and activation of PAR 2 on monocytoid cells contributed to the neuroinfl ammatory/degenerative process in EAE. Of interest, PAR 2 expression is up-regulated on monocytes upon diff erentiation to macrophages (22) , and its activation leads to the production of proinfl ammatory cytokines IL-1β, IL-6, and IL-8 (21) . A concomitant localized increase in tryptic serine proteinases, which act as potential activators of PAR 2 , may accentuate PAR 2 -mediated eff ects in the context of MS/EAE neuroinfl ammation. Indeed, there is also a report describing the role of PAR 2 in dendritic cell development (36) , indicating that dendritic cells do not spontaneously develop from the bone marrow cells of PAR 2 -defi cient mice after IL-4/GM-CSF ARTICLE treatment, despite diff erentiating to mature dendritic cells in the presence of infl ammatory mediators (36) . In our hands, treatment of bone marrow cells from WT and PAR 2 KO animals with IL-4/GM-CSF led to the generation of morphologically indistinguishable dendritic cells, which matured normally after LPS treatment (not depicted). Nonetheless, given the administration of adjuvants upon MOG immunization with the resulting immune activation, it is unlikely that diff erences in antigen presentation exert major eff ects on the ensuing autoimmune processes in the present studies.
Although many studies have indicated proinfl ammatory roles for PAR 2 in respiratory, gastrointestinal, musculoskeletal, skin, and peripheral nervous systems (23, (37) (38) (39) (40) (41) (42) , PAR 2 agonists have also been shown to be benefi cial in some mouse models of mucosal infl ammation (43, 44) . These studies underscore the diff erent roles played by PAR 2 based on the individual cell type and specifi c animal model or disease context. Elucidation of mechanisms leading to altered receptor expression and diff erential downstream eff ects, together with identifying specifi c activating proteinases, will permit the development of new therapeutic strategies for modulating detrimental eff ects of infl ammation in the nervous system.
MATERIALS AND METHODS
Human brain tissue samples. CNS tissue (frontal lobe white matter) was collected at autopsy with consent from each experimental group (MS, n = 6; non-MS, n = 6) and stored at −80°C as described previously (45) (46) (47) . Brain samples from MS and non-MS patients were obtained from the Laboratory for Neurological Infection and Immunity Brain Bank, University of Alberta. Normal-appearing frontal white matter was homogenized, lysed in TRIzol (Invitrogen), and used in real-time PCR analyses as described previously (48) . The MS patient group (female/male, 4:2) was classifi ed as relapsingremitting (n = 1), primary progressive (n = 2), and secondary progressive (n = 3; mean age 57 ± 10 yr) with estimated disability status scores of 7-10 at death. The non-MS group (female/male, 3:3) was classifi ed as anoxic encephalopathy (n = 1), HIV-1 infection (encephalitis, n = 1; toxoplasmosis encephalitis, n = 1), Alzheimer's disease (n = 2), and sepsis (n = 1; mean age 61 ± 12 yr). Human CNS sections from non-MS and MS patients with acute demyelinating lesions were provided by A. Clark (University of Calgary, Calgary, Canada).
Cell cultures.
Mouse primary astrocyte cultures were established from CNS tissue of 2-d-old PAR 2 WT and KO mice as described previously (49) . Cells were cultured in MEM containing 10% FBS, 1 mM sodium pyruvate, and 2 mM l-glutamine. Mouse bone marrow-derived macrophages were isolated from the pelvic and femoral bone marrow of adult PAR 2 WT and KO mice (50) as described previously (47, 51) . Bone marrow cells were cultured in DMEM containing 10% FBS, 10% L929 cell-conditioned medium as a source of M-CSF, and 2 mM l-glutamine (Invitrogen). Cells were incubated in 10% CO 2 for 5 d before additional treatments. Macrophages or astrocytes were treated with 100 ng/ml LPS for 8 h before TRIzol lysis and RNA extraction. For PAR 2 activation experiments, cells were treated with 100 μM PAR 2 AP (SLIGRL-NH 2 ) or mAP (LSIGRL-NH 2 ) for 4 h (Peptide Synthesis Facility, University of Calgary). Cells were then washed twice and fresh AIM-V serum-free medium (Invitrogen) was added. Media was harvested 24 h later and stored at −80°C for subsequent oligodendrocyte toxicity experiments. Oligodendrocytes were isolated from adult SpragueDawley rat brains and plated in polyornithine-coated chamber slides (Nunc) as described previously (52) . Oligodendrocytes were maintained in MEM containing 5% FBS, 0.1% dextrose, 2 mM l-glutamine, and 1 mM sodium pyruvate for 5 d. Oligodendrocytes were then treated with the supernatants of PAR 2 AP-treated macrophages or astrocytes for 24 h before fi xation and immunostaining. Human PBMCs from healthy individuals were isolated by density separation over Ficoll-hypaque and seeded in 24-well plates in RPMI containing 10% FBS. Cells were treated with 5 μg/ml phytohemagglutinin for 24 h before staining and fl ow cytometric analysis.
Immunohistochemistry. Formalin-fi xed, paraffi n-embedded sections of human brain tissue (frontal lobe) were deparaffi nized and rehydrated using decreasing concentrations of ethanol. Antigen retrieval was performed by boiling the slides in 0.01 M trisodium citrate buff er, pH 6, for 10 min followed by incubation with 0.3% hydrogen peroxide to block endogenous peroxidases. Sections were then preincubated with 10% normal goat serum, 0.2% Triton X-100 overnight at 4°C to block nonspecifi c binding. To detect PAR 2 immunoreactivity, slides were incubated overnight at 4°C with a rabbit polyclonal antibody (B5) raised against rat PAR 2 (1:500; reference 53) (GPN SKG RSL IGR LDT 46P YGG C; 1/500) diluted in 5% normal goat serum, 0.2% Triton X-100 (47) . A secondary biotinylated goat anti-rabbit antibody followed by avidin-biotin-peroxidase complexes (Vector Laboratories) and 3,3′-diaminobenzidine tetrachloride (Vector Laboratories) were used for single labeling. For double labeling with anti-CD45 (1:100; Zymed Laboratories) and anti-GFAP (1:50; BD Biosciences) mouse monoclonal antibodies, an alkaline phosphatase-conjugated goat anti-mouse antibody (Jackson ImmunoResearch Laboratories) followed by NBT/BCIP substrate (Vector Laboratories) were used.
Immunofl uorescence and confocal laser scanning microscopy. Rabbit polyclonal anti-PAR 2 (B5) antibody (53) together with mouse monoclonal anti-GFAP (1:50; BD Biosciences) and goat polyclonal anti-PAR 2 antibody (1:50; Santa Cruz Biotechnology, Inc.) together with rabbit polyclonal antibody against Iba-1 (1:500; Wako) followed by appropriate secondary antibodies were used to detect PAR 2 immunoreactivity and localization in lumbar spinal cords of mice (47) . Antibodies against Iba-1 (1:500; Wako), CD3 (1:100; Santa Cruz Biotechnology, Inc.), and MBP (1:1,000; Sternberger Monoclonals) followed by appropriate secondary antibodies were used to detect macrophage/microglial, T lymphocyte, and myelin immunoreactivity. Slides were examined on an Olympus Fluoview (FV300) confocal laser scanning microscope. For quantifi cation, Iba-1 or CD3-immunopositive cells were counted using a regular fl uorescent microscope (Axioskop2; Carl Zeiss MicroImaging, Inc.) in ventral, lateral, and dorsal columns of the spinal cord white matter. Quantitative analysis of MBP reactivity was performed using Scion Image software (Scion Corporation). Cultured oligodendrocytes derived from adult rat brains were stained with O1 anti-galactocerebroside monoclonal antibody (provided by V.W. Yong, University of Calgary, Calgary, Canada) that recognizes mature oligodendrocytes, followed by a Cy3-conjugated goat anti-mouse antibody. Slides were scanned by laser scanning confocal microscope, and Scion Image software was used to measure the surface area of O1-immunopositive oligodendrocytes (52).
Real-time RT-PCR. Cultured cells, human brain (frontal lobe white matter), or lumbar spinal cords from mice were homogenized in TRIzol (Invitrogen) according to the manufacturer's guidelines. Total RNA was isolated and dissolved in diethylpyrocarbonate-treated water, and 1 μg RNA was used for the synthesis of complementary DNA and subsequent PCR as described previously (48) . Primer sequences were as follows: human GAPDH, 5′ primer: 5′-A G C C T
T C T C C A T G G T G G T-G A A G A C -3′,3′primer: 5′-C G G A G T C A A C G G A T T T G G T C G -3′; human PAR 2 , 5′ primer: 5′-C T G G C C A T T G G G G T C T T T C T G T T C -3′, 3′ primer: 5′-G G C C C T C T T C C T T T T C T T C T C T G A -3′; human trypsinogen, 5′ primer: 5′-T C A G C G A A C A G T G G G T G G T A T C A G -3′, 3′ primer: 5′-G A G G G G C G G T G G G C A G A G -3′
; mouse PAR 2 , 5′ primer: 5′-TGGCCATTGGAGTCTTCCTGTT-3′, 3′ primer: 5′-TAGCC-CTCTGCCTTTTCTTCTC-3′; and mouse trypsinogen, 5′ primer: 5′-ATCTCTGGCTGGGG CAACA C T C-3′, 3′ primer: 5′-CTAGGAA-G C C A G C A C A G A C C A T-3′. Mouse trypsinogen primers were designed based on the mouse mesotrypsin (mouse serine protease 3, Prss3) sequence. The other mouse oligonucleotide primer sequences have been reported previously (54) . Semiquantitative analysis was performed by monitoring in real time the increase of fl uorescence of the SYBR green dye on an i-Cycler (Bio-Rad Laboratories) as reported previously (48) . All data were normalized against the GAPDH mRNA levels and expressed as fold increases relative to controls ± SE.
Induction and assessment of EAE. 10-12-wk-old female PAR 2 homozygous KO mice (50) and littermate homozygous WT controls were used for EAE induction. Age-matched female mice were injected subcutaneously with 50 μg MOG (MOG peptide; prepared by the Peptide Synthesis Facility, University of Calgary) emulsifi ed in 100 μl of complete Freund's adjuvant (Difco Laboratories; reference 47). Animals received intraperitoneal injections of pertussis toxin (0.3 μg; List Biological Laboratories) at the same time as MOG immunization and 48 h later. Vehicle-treated animals were only injected with complete Freund adjuvant and pertussis toxin. Animals were assessed daily for EAE severity for 30 d using a 0-5 rating scale as reported previously (55) . Animals were killed by cardiac puncture under ketamine/xylazine anesthesia. Spinal cords were removed and fi xed in 4% neutral buff ered formalin before paraffi n embedding or lysed in TRIzol for RNA extraction. All experiments were approved by the University of Calgary Animal Care Committee.
Histological analysis. Formalin-fi xed spinal cords of EAE or vehicletreated animals were embedded in paraffi n before sectioning (56). 4-μm sections from lumbar spinal cords were stained with Bielschowsky's silver impregnation method (33) . Five randomly chosen fi elds in each animal's white matter were scanned and photographed using a microscope (Axioskop2; Carl Zeiss MicroImaging, Inc.) and the Spot imaging system (Diagnostic Instruments). The number of silver-positive axons was quantifi ed in square millimeters using Scion Image software (Scion Corporation).
T cell proliferation and fl ow cytometric analysis. Splenocytes isolated from the spleens of nonimmunized animals by density separation over Ficollhypaque were γ irradiated, suspended at a density of 2 × 10 6 cells/ml, and incubated with 40 μg/ml MOG peptide for 30 min (57) . Splenocytes incubated with vehicle were used as control. Draining lymph nodes were isolated from MOG-immunized PAR 2 WT and KO animals 7 d after immunization. Lymph nodes were homogenized in PBS, and lymphocytes isolated from dissociated lymph nodes were washed and suspended at a density of 2 × 10 6 cells/ml. Splenocytes and lymphocytes were plated 1:1 in 96-well U-bottom microtiter plates. Cells were incubated at 37°C for 48 h before adding 1 μCi [ 3 H]thymidine (GE Healthcare) to each well. Cells were harvested after 24 h and counted on a liquid scintillation counter. Intracellular cytokine assay was performed using a cytofi x/cytoperm kit according to the manufacturer's guidelines (BD Biosciences). In brief, Golgistop protein transport inhibitor was added to splenocyte/lymphocyte cocultures 48 h after plating. Cells were harvested after 12 h and immunostained using PerCPlabeled anti-mouse CD3 (1:50), FITC-labeled anti-mouse CD4 (1:50), and PE-labeled anti-IFN-γ (1:50) monoclonal antibodies. All monoclonal antibodies were purchased from BD Biosciences. For PAR 2 immunodetection, cultured PBMCs were stained with B5 rabbit anti-PAR 2 antibody followed by Alexa 488-conjugated goat anti-rabbit secondary antibody. FACS analysis was performed on a FACSCalibur apparatus using CELLQuest software (Becton Dickinson).
